| CAS NO: | 2306193-99-5 |
| 包装: | 50mg |
| Cas No. | 2306193-99-5 |
| 别名 | VHL ligand 3; E3 ligase Ligand 19 |
| Canonical SMILES | CC1=C(SC=N1)C2=CC=C(CNC([C@@H]3C[C@@H](O)CN3C([C@@H](NC(C4(CC4)F)=O)C(C)(C)C)=O)=O)C(O)=C2 |
| 分子式 | C26H33FN4O5S |
| 分子量 | 532.63 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Functionalized von-Hippel-Lindau protein ligand (VHL) for PROTAC(R) research and development; incorporates an E3 ligase ligand with terminal hydroxyl ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. PROTAC(R) is a registered trademark of Arvinas Operations, Inc., and is used under license. Zoppi et al (2019) Iterative design and optimization of initially inactive Proteolysis Targeting Chimeras (PROTACs) identify VZ185 as a potent, fast, and selective Von Hippel-Lindau (VHL) based dual degrader probe of BRD9 and BRD7. J.Med.Chem. 62 699 PMID:30540463 |Girardini et al (2019) Cereblon versus VHL: hijacking E3 ligases against each other using PROTACs. Bioorg.Med.Chem. 27 2466 PMID:30826187 |Farnaby et al (2019) BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat.Chem.Biol. 15 672 PMID:31178587 |Maniaci et al (2017) Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation. Nat.Commun. 8 830 PMID:29018234 |
m.cnreagent.com